Please select the option that best describes you:

When treating borderline resectable pancreatic adenocarcinoma patients with neoadjuvant chemoradiation, do you treat the elective nodal regions or the primary alone?  

 Is your approach similar in unresectable disease? Is there evidence to support one approach over the other? 



Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign in or Register to read more